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Abstract
Rationale Anterior cingulate cortex (ACC) glutamatergic abnormalities are reported in treatment-resistant schizophrenia (TRS) and
implicated in functional dysconnectivity and psychopathology. Preclinical evidence indicates riluzole reduces synaptic glutamate.
However, it is unknown whether riluzole can modulate glutamate metabolite levels and associated functional connectivity in TRS.
Objectives To examine the relationship between glutamatergic function and cortical connectivity and determine if riluzole can
modulate glutamate metabolite levels and cortical functional connectivity in TRS.
Methods Nineteen TRS patients and 18 healthy volunteers (HV) underwent magnetic resonance imaging consisting of MR spectros-
copymeasuringACCglutamate plus glutamine (Glx), fMRImeasuring restingACC-functional connectivity, and arterial spin labelling
measuring regional cerebral blood flow (rCBF), and clinical measures. They then received 50 mg riluzole twice daily for 2 days when
imaging was repeated.
Results Baseline (pre-riluzole) Glx levels were correlated directly with negative symptom severity (r= 0.49; p = 0.03) and inversely
with verbal learning in TRS (r= − 0.63; p = 0.002), but not HV (r =− 0.24; p= 0.41). Connectivity between the ACC and anterior
prefrontal cortex (aPFC) was correlated with verbal learning in TRS (r = 0.49; p= 0.04), but not HV (r = 0.28; p = 0.33). There was a
significant group × time interaction effect on Glx levels (p < 0.05) and on ACC connectivity to the aPFC (p < 0.05, FWE-corrected).
Riluzole decreased Glx and increased ACC-aPFC connectivity in TRS relative to HV. Change in Glx correlated inversely with change
in ACC-aPFC connectivity in TRS (r= − 0.52; p= 0.02) but not HV (r = 0.01; p = 0.98). Riluzole did not alter rCBF (p > 0.05),
indicating absence of a non-specific blood flow effect.
Conclusion Results indicate glutamatergic function and cortical connectivity are linked to symptoms and cognitive measures and
that it is possible to pharmacologically modulate them in TRS.
Keywords Schizophrenia . Psychosis . Treatment resistant . Glutamate . Riluzole . Spectroscopy .MRS . Negative . Cognitive
Introduction
Schizophrenia has a worldwide lifetime prevalence of ap-
proximately 1% (McGrath et al. 2008). It is a leading
contributor to global disease burden, partly because many
patients do not respond sufficiently to currently available
treatments (Howes et al. 2017). Indeed, approximately
two-thirds of patients with schizophrenia show a subopti-
mal symptomatic response to standard antipsychotic ad-
ministration, which all target dopamine D2 receptors
(Howes et al. 2017; Meltzer 1997). Future drug develop-
ment therefore requires a greater understanding of the bi-
ological processes underlying the illness to identify new
therapeutic targets (Howes and Kapur 2014).
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Converging lines of evidence implicate glutamatergic dys-
function in the pathophysiology of schizophrenia (Javitt 2007;
Ripke et al. 2014). The N-methyl-D-aspartate receptor
(NMDAR) hypofunction model of schizophrenia proposes
that dysfunction of NMDARs on parvalbumin-containing γ-
aminobutyric acid–ergic interneurons results in disinhibition
of excitatory pyramidal cells leading to an increase in gluta-
matergic activity (Lisman et al. 2008; Olney and Farber 1995;
Stone et al. 2007). Administration of the NMDAR antagonist
ketamine increases glutamatergic metabolites in the frontal
cortex (Moghaddam et al. 1997; Stone et al. 2012); induces
mental experiences characteristic of positive, negative, and
cognitive symptoms of schizophrenia in healthy volunteers;
and exacerbates psychotic symptoms in patients with schizo-
phrenia (Cheng et al. 2018; Javitt and Zukin 1991). Meta-
analysis of in vivo magnetic resonance spectroscopy (MRS)
studies has shown an elevation in glutamate plus glutamine
(Glx) across several brain regions in schizophrenia (Merritt
et al. 2016), with some, although not all, studies observing
that the magnitude of regional glutamate alterations correlates
with the severity of negative and cognitive symptoms (Merritt
et al. 2013).
There is emerging evidence that glutamate dysfunction
may play a particular role in treatment-resistant symptoms
(Egerton et al. 2017). Although not a universal finding
(Goldstein et al. 2015), studies using proton magnetic reso-
nance spectroscopy (1H-MRS) have observed that levels of
glutamatergic metabolites are particularly elevated in the an-
terior cingulate cortex (ACC) in treatment-resistant schizo-
phrenia (TRS) compared to levels in patients who respond to
antipsychotic treatment, and healthy volunteers (Demjaha
et al. 2014; Egerton et al. 2012; Goldstein et al. 2015;
Mouchlianitis et al. 2016).
It has also been suggested that glutamatergic dysfunction
could underlie cortical functional dysconnectivity in schizo-
phrenia (Stephan et al. 2006). Indeed, schizophrenia is asso-
ciated with decreased resting state functional connectivity
(Dong et al. 2018), including deficits in functional connectiv-
ity between the ACC and frontal cortex that are present from
onset of illness and the prodromal phase, and that are related to
symptom severity (Lord et al. 2011). Moreover, reductions in
ACC-prefrontal cortex functional connectivity have been ob-
served in schizophrenia patients with persistent auditory hal-
lucinations compared with patients without hallucinations,
suggesting that alterations in ACC-prefrontal connectivity
may contribute to at least some treatment-resistant symptoms
(Alonso-Solis et al. 2015).
Riluzole (2-amino-6-trifluormethoxy benzothiazole) is a
drug licenced for amyotrophic lateral sclerosis that acts to
reduce synaptic release of glutamate by inhibiting voltage-
gated sodium channels and calcium currents (Bellingham
2011; Doble 1996). It also enhances astrocytic glutamate re-
uptake (Frizzo et al. 2004), increases cortical glutamate
metabolism (Chowdhury et al. 2008), and reduces the amount
of releasable presynaptic glutamate (Lazarevic et al. 2018).
Riluzole thus represents a promising agent to target gluta-
matergic dysfunction in schizophrenia. Indeed, a recent
randomised controlled trial in 50 patients with schizophrenia
and treatment-resistant symptoms observed that adjunctive
riluzole significantly decreased negative symptom severity
within 4 weeks compared to a placebo group (Farokhnia
et al. 2014). The mechanism underlying this effect is un-
known, but riluzole has been shown to alter ACC glutamater-
gic metabolite concentrations in autism spectrum disorder,
increasing prefrontal concentrations of Glx relative to
gamma-aminobutyric acid (GABA) (Ajram et al. 2017), and
in bipolar depression, increasing the ACC glutamine to gluta-
mate ratio (Brennan et al. 2010). Moreover, in ASD, riluzole
reduces abnormal prefrontal connectivity (Ajram et al. 2017).
However, it is unknown if riluzole is able to alter glutamater-
gic signalling or cortical connectivity in schizophrenia.
In view of this, we aimed to test the hypotheses that riluzole
would reduce Glx levels and increase cortical connectivity in
individuals with schizophrenia and antipsychotic-resistant
symptoms, and that these effects would be related to each
other. We used a healthy volunteer group to enable normative
comparisons and control for non-specific effects. Based on
preclinical evidence that riluzole does not alter glutamatergic
indices when glutamate function is normal (Rizzo et al. 2017),
we predicted that riluzole would have no effects on gluta-
matergic metabolites or ACC connectivity in healthy
volunteers.
Methods
Participants and clinical measures
Twenty-one participants meeting DSM-IV criteria for schizo-
phrenia were recruited from outpatient services within the
South London and the Maudsley NHS Foundation Trust
(Beck et al. 2014). Nineteen healthy volunteers with no histo-
ry of psychiatric illness were recruited from the local popula-
tion to provide a normative comparison. Exclusion criteria for
all participants were as follows: inability to provide written
informed consent; co-morbid drug or alcohol abuse/
dependence; a history of liver disease or transaminitis > 2
times the upper limit of normal (owing to the potential for
riluzole to cause liver dysfunction (Castells et al. 1998)); any
contraindication to MRI scanning at 3 T (e.g. metallic im-
plants); any comorbidity that could compromise scanning
safety (e.g. severe asthma); pregnancy/breast feeding; and
the use of medication with recognised effect on glutamatergic
signalling, including clozapine, lamotrigine, lithium, carba-
mazepine, opiates, and psychostimulants.
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Treatment-resistant schizophrenia was defined as presence
of at least one positive and one negative symptom rated as ≥ 4
on the Positive and Negative Syndrome Scale (PANSS) (Kay
et al. 1987), indicative of at least moderate severity, and a
score of < 60 on the Global Assessment of Functioning scale
(GAF) (APA 2013) indicative of at least moderate functional
impairment, despite 2 trials of an antipsychotic. To provide
insight into the range of illness severity within the TRS cohort,
severity of illness was defined according to criteria set out by
Leucht and colleagues that classifies total PANSS scores of
58–74 as mild-moderate illness, 75–94 as moderate-marked
illness, and 95–115 as marked-severe illness (Leucht et al.
2005). A sufficient antipsychotic trial was defined as one giv-
en for at least 6 weeks with evidence of concordance (based
on examination of patient records) and at a target dose recom-
mended by the relevant manufacturer’s summary of product
characteristics/at a total daily dose equivalent to or greater
than 600 mg chlorpromazine. Patients were required to be
on a stable antipsychotic regimen, with no change in treatment
dose in the 6 weeks prior to study participation. Antipsychotic
plasma levels were measured to assess concordance, as previ-
ously described (McCutcheon et al. 2018). This approach to
defining treatment-resistant schizophrenia conformed with at
least the minimum requirements provided by Treatment
Response and Resistance in Psychosis (TRRIP) working
group consensus guidelines (Howes et al. 2017), summarised
in eTable 1. Clinical Global Impression (CGI)-Severity (Guy
1976) scores were also recorded. All participants underwent
neurocognitive testing with the Rey Auditory and Verbal
Learning Test (AVLT) (Schmidt 1996), a well-established tool
to assess cognitive functioning in schizophrenia (Zaytseva
et al. 2018). AVLT total score (the number of words correctly
recalled, summed across the five immediate recall trials) was
used to assess verbal-learning performance (Karilampi et al.
2007), a recognised neurocognitive deficit in TRS (Joober
et al. 2002). Participants underwent two MRI scans. On both
scan days, all participants underwent urine testing for cocaine,
amphetamine, cannabis, opiate, and benzodiazepine use.
Administration of riluzole
We used a 2-day riluzole challenge because a previous 1H-
MRS study showed an effect of riluzole on ACC glutamate
and glutamine levels in bipolar depression using this treatment
duration (Brennan et al. 2010). After the baseline MRI scan,
the 2-day course of riluzole was given at a dose of 50 mg
every 12 h, the dose and frequency recommended in the treat-
ment of ALS (Miller et al. 2012). Since peak plasma levels of
riluzole occur 1–1.5 h after oral administration (LeLiboux
et al. 1997), the final (fourth) dose was taken 1.5 h before
the second scan commenced. Adherence was ensured by
SMS messaging reminders to participants, and inspection of
medication containers at presentation to the follow-up scan.
1H-MRS acquisition
Scans were acquired using MRI at 3 T (General Electric,
Chicago, IL, USA). All scans were performed at the same
time of day (mid-morning). Each scanning session com-
menced with a localizer, standard axial T2-weighted fast
spin echo scan (TR/TE = 4380/55.72) and a T1-weighted
structural scan (TR/TE = 7.312/3.01). The T1-weighted
image was used to plan 1H-MRS voxel placement, and
for calculation of 1H-MRS voxel tissue content. The 1H-
MRS voxel was placed in the anterior cingulate cortex
(ACC). The ACC voxel was defined from the midline
sagittal localizer, with the centre of the 20 mm × 20 mm ×
20 mm voxel placed 16 mm above the genu of corpus
callosum perpendicular to the AC–PC line (Fig. 1). 1H-
MRS spectra (Point RESolved Spectroscopy; TE = 30 ms;
TR = 3000 ms; 96 averages; bandwidth = 5 kHz, number
of data points = 4096) were acquired using the standard
GE PROBE (proton brain examination) sequence.
Additional unsuppressed water reference spectra (16 aver-
ages) were acquired for eddy current correction and water
scaling.
pCASL acquisition
To determine if changes in ACC-Glx or connectivity were
secondary to changes in regional blood flow, we assessed
the effect of riluzole on cerebral blood flow in TRS pa-
tients and HV using arterial spin labelling MR imaging.
For measurement of regional cerebral blood flow (rCBF),
a 3D pseudo-continuous ASL (pCASL) acquisition was
used. Arterial blood was labelled using a long (1.5 s) train
of adiabatic radio frequency pulses. After a post-labelling
delay of 1.5 s, perfusion images were acquired with a 3D
Fast Spin Echo (FSE) stack-of-spirals multi-shot readout
(TE/TR = 32 ms/5500 ms; ETL = 64) (Dai et al. 2008).
CBF maps were computed in physiological units of ml
blood per 100 mg of tissue per minute, with a voxel size
of 1 × 1 × 3 mm3. During the scan, participants were
instructed to keep their eyes open and look at a fixation
cross.
Resting state fMRI acquisition
Resting state fMRI was acquired using a multi-echo echo-
planar imaging (ME-EPI) sequence: TR = 2.5 s; TE = 12, 28,
44, 70ms; 240 time-points; slice thickness = 3mm; slice spac-
ing = 4 mm; spatial positions, 32; flip angle 80°; field of view
240 mm; matrix size 64 × 64; scan time 10 min. During the
scan, participants were instructed to keep their eyes open and
look at a fixation cross.
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Fig. 1 1H-MRS voxel position and example spectra in the anterior cingulate cortex. NAA, N-acetylaspartate; Glx, glutamate + glutamine; Cr, creatine;
Chol, choline; MI, myoinositol
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1H-MRS analysis
Spectra were analysed using LC Model version 6.3-1L 44.
Voxel grey matter (GM), white matter (WM), and cerebrospi-
nal fluid (CSF) content for each subject were derived by
extracting the location of the voxel from the spectra file
headers and using an in-house program to calculate the per-
centage of GM, WM, and CSF using the segmented T1-
weighted images. Segmentation was performed using the
‘segment’ function of SPM12. Water-scaled metabolites were
corrected for CSF using the formula: metabolite corrected =
metabolite concentration × [proportion WM + (1.21 × propor-
tionGM) + (1.548 × proportion CSF)]/(proportionWM+ pro-
portion GM). The formula assumes a CSFwater concentration
of 55,556 mol/m3 with the LCModel default brain water con-
centration of 35,880 mol/m3 (Gasparovic et al. 2006; Kreis
et al. 1993). Poor-quality scans, as defined by poorly fitted
metabolite peaks (Cramér–Rao minimum variance bounds >
20%, and signal to noise ratio < 8, as reported by LCModel)
were excluded from further analysis.
pCASL analysis
Computation of the CBF values was performed in the scanner
following the methodology outlined in the recent ASL con-
sensus paper (Alsop et al. 2015). Individual CBF maps were
transformed to Montreal Neurological Institute (MNI) space
using the Automatic Software for ASL Processing (ASAP)
toolbox (Abad et al. 2016) running in SPM-8 under Matlab
6.5. Default pre-processing options were used for skull-strip-
ping, co-registration to the subject’s 3D anatomical scan, and
normalisation to the MNI template based on unified segmen-
tation. The normalised maps were finally smoothed using an
8-mm kernel. Segmentation was performed using the ‘seg-
ment’ function of SPM12.
Resting state fMRI analysis
After realignment and slice timing correction, multi-echo in-
dependent component analysis was used to denoise the resting
state data (Kundu et al. 2013). After performing an indepen-
dent component analysis on the unprocessed resting fMRI
data, the dependence of each component on echo time (TE)
is quantified. Genuine BOLD T2* signal is linearly related to
TE, whereas artefactual signal is not. As a result, it is then
possible to separate resting state networks from noise compo-
nents. The time courses from the non-BOLD components are
then used as regressors for data cleaning, along with white
matter and CSF time courses. Temporal band bass filtering
was performed using FSL with sigma = 50 (Smith et al.
2004). Normalisation toMNI space was then performed using
the CONN v18 functional connectivity toolbox (Whitfield-
Gabrieli and Nieto-Castanon 2012). Segmentation was per-
formed using FSL FAST.
Statistical analysis
The effects of riluzole on 1H-MRS metabolite levels in TRS
compared with HV over time in the ACC were determined
using a two-way (group × time) repeated measures ANOVA,
with the primary outcome defined a priori as Glx levels.
Outliers in each group (patient and control, pre- and post-
riluzole) were identified using the Tukey method (Tukey
1977), and analyses performed with these removed. Where a
significant group × time interaction was recorded, post hoc
unpaired t tests were performed to examine differences in
Glx between groups pre- and post-riluzole, and paired t tests
performed to examine differences in Glx within groups over
time. Exploratory analyses were also performed for changes in
glutamate and N-acetylcysteine levels over time (both CSF-
corrected and referenced to creatine).
The effects of riluzole on rCBF in TRS compared with HV
were also examined using a repeated measures ANOVA im-
plemented in SPM-8. We performed SPM analyses both at a
whole brain level (cluster defining threshold p < 0.001, uncor-
rected for multiple comparisons), and in the ACC. The ACC
region of interest was created of the same dimension as the
MRS voxel (Fig. 1). We employed the uncorrected threshold
so as to increase the sensitivity to potential effects of riluzole
upon blood flow.
For the resting state connectivity analysis, voxel-wise con-
nectivity maps for each participant were derived by computing
Pearson correlations between the signal average over each
seed region, and the signal at each voxel over the entire brain.
These were then converted to normally distributed Fisher’s z
maps to allow second-level general linear model analyses. At
the second level, a seed to voxel analysis was performed with
a view to examining the effect of riluzole on ACC-frontal
connectivity. Six ACC seeds were selected a priori from 32
ACC seeds previously characterised by Margulies and col-
leagues (Margulies et al. 2007), who in observing functional
heterogeneity within the ACC identified six seeds with evi-
dence of functional connectivity to the frontal cortex (see
eAppendix 1 and eTable 2 for further details). Connectivity
maps between groups (TRS group and HV group, pre- and
post-riluzole) were contrasted with each other for the six ACC
seeds. A cluster was considered statistically significant if it
passed a cluster defining threshold of p < 0.001 and cluster-
level threshold of p < 0.05 FWE corrected.
Spearman’s correlation coefficients were used to examine
the relationship between changes in imaging variables over
time (e.g. changes in ACC 1H-MRS metabolite levels and
changes in ACC-cluster connectivity). Moreover, to help in-
terpret the clinical relevance of our findings, pre-riluzole,
Spearman’s correlation coefficients were also used to examine
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the relationship between imaging variables (e.g. ACC 1H-
MRS metabolite levels) and clinical (PANSS) and
neurocognitive (AVLT) scores. Spearman correlation coeffi-
cients were employed owing to the measure being robust to
the influence of outliers (King 1992). All non-SPM statistical
analysis was performed using SPSS software (version 22.0,
Chicago, IL), for which statistical significance was defined as
p < 0.05.
Results
Sample characteristics
Participant demographic and clinical measures are presented
in Table 1. Riluzole was well tolerated in all participants and
no adverse effects were reported. Of the patients with TRS,
nine were receiving long-acting injectable antipsychotic med-
ication. Five patients were receiving risperidone, one
zuclopenthixol decanoate, two aripiprazole, five paliperidone,
five olanzapine, three amisulpride, and one quetiapine. Two
patients were receiving dual antipsychotic treatment. Plasma
antipsychotic levels were in the therapeutic range for all par-
ticipants. On both scan days, all participants tested negative on
urine testing for cocaine, amphetamine, cannabis, opiates, and
benzodiazepine use.
Pre- and post-riluzole MRI datasets were available in 19 of
the 21 patients, as 2 participants chose not to continue with the
study after the first scan. Pre-and post-riluzole MRI datasets
were available in 18 of the 19 healthy controls, as scanner
failure precluded a follow-up scan for one participant.
Nineteen TRS patients and 18 healthy volunteers were includ-
ed in 1H-MRS analyses. Nineteen TRS patients and 18
healthy volunteers were included in rCBF analyses, and 19
TRS patients and 17 healthy volunteers were included in rest-
ing state fMRI analyses (owing to scanner failure with one
resting state sequence in the HV group). For those TRS pa-
tients who completed the study, 37% patients presented with
mild-moderate symptoms, 58% presented with moderate-
severe symptoms, and 5% with marked-severe symptoms.
There were no significant differences in values relating to
1H-MRS data quality or voxel tissue content in patients com-
pared with controls over time (eTable 3). For all 1H-MRS data,
data were reported for which all individual Cramér Rao Lower
Bounds were below 20%, signal to noise ratio values were
above 8, and no spectra were excluded based on poor quality.
Effect of riluzole on glutamate metabolites,
ACC-frontal connectivity, and rCBF
There was a significant group by time interaction for Glx
levels in the ACC (f = 4.46; p = 0.04; Fig. 2a; Table 2).
Outliers identified using the Tukey method are demonstrated
in eFigure 1. Results were similar after removal of outliers (f =
7.16; p = 0.01). On post hoc analysis, ACC-Glx levels pre-
and post-riluzole were not significantly different in TRS com-
pared with HV, nor was there any difference in ACC-Glx
within groups over time (all p ≥ 0.05, eTable 4). Specifically,
riluzole was associated with a numerical decrease in ACC-Glx
in TRS, although statistical significance was not reached (t =
− 2.08; p = 0.05). There were no significant group by time
effects for ACC glutamate or N-acetyl asparate levels
(eTable 5). There was no significant group by time interaction
for creatine-scaled Glx levels (f = 3.27; p = 0.08), nor for
creatine-scaled glutamate or N-acetyl aspartate levels
(eTable 6). There were no significant group by time effects
for rCBF, either in the ACC or at whole brain level (Table 2).
For ACC and whole brain CBF, there was no significant
Table 1 Demographics and where appropriate clinical measures of
patients and healthy volunteers included in the primary repeated
measures 1H-MRS analysis. Where appropriate, data are reported as
mean (standard deviation). CGI Clinical Global Impression score, GAF
Global Assessment of Functioning score, PANSS Positive and Negative
Syndrome Scale scores, AVLTAuditory and Verbal Learning Test
Patients (n = 19) Healthy volunteers (n = 18) Statistic
Age (years) 39.68 (10.92) 36.28 (9.17) t = 1.02; df = 35; p = 0.31
Gender (female/male) 3/16 3/15 χ2 = 0.01; p = 0.94
AVLT score 35.58 (15.36) 59.86 (11.69)* t = 4.95; df = 31; p < 0.0001
PANSS—positive 18.47 (3.03)
PANSS—negative 19.58 (5.48)
PANSS—general 34.42 (7.96)
PANSS—total 72.47 (10.19)
CGI 4.15 (0.77)
GAF 52.1 (9.98)
Severity of illness Mild-moderate, 7/19 (37%)
Moderate-marked, 11/19 (58%)
Marked-severe, 1/19 (5%)
*Data available for 14 healthy volunteers
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difference between TRS and HV pre- and post-riluzole, nor
was there any difference in CBF within groups over time (all
p > 0.05, eTables 7 and 8).
There was a significant group × time interaction for con-
nectivity between the ACC seed sited at MNI coordinate (± 5,
27, 21) with a cluster sited within the right anterior prefrontal
cortex (aPFC) (Fig. 2b). For this cluster, at baseline, ACC-
frontal connectivity was lower in patients compared with
healthy volunteers, and this outcome reversed following
riluzole (Fig. 2c). We did not observe a significant interaction
for the five other ACC seeds examined.
Correlations between Glx and functional connectivity
Pre-riluzole, ACC-Glx correlated inversely with degree of
ACC-aPFC functional connectivity in TRS (r = − 0.46; p =
0.047), but not HV (r = 0.09; p = 0.74) (Fig. 3a). Post-riluzole,
no significant association was observed between ACC-Glx
and ACC-aPFC functional connectivity in TRS (r = − 0.16;
p = 0.52) or HV (r = 0.14; p = 0.61) (Fig. 3b). Changes with
riluzole in functional connectivity between the ACC and
aPFC cluster were inversely correlated with changes in
ACC-Glx levels in TRS patients (r = − 0.52; p = 0.02), but
not HV (r = 0.01; p = 0.98) (Fig. 3c).
Correlations between imaging variables
and symptom severity
Pre-riluzole, increased ACC-Glx was associated with lower
verbal learning scores in TRS (r = − 0.63; p = 0.002) but not
HV (r = − 0.24; p = 0.41) (Fig. 4a). Moreover, increased
ACC-Glx was associated with elevated PANSS negative
scores in TRS (r = 0.49; p = 0.03) (Fig. 4b). Pre-riluzole, low-
er ACC-aPFC functional connectivity was associated with
lower verbal learning scores in TRS (r = 0.47; p = 0.04), but
not HV (r = 0.28; p = 0.33) (Fig. 4c). There were no other
significant correlations between baseline PANSS (positive,
general, or total) or AVLT scores and ACC-Glx/ACC-aPFC
connectivity (all p > 0.05, eTable 9).
Discussion
Our main findings are that riluzole reduces ACC-Glx concen-
trations and normalises ACC-frontal hypoconnectivity in pa-
tients with TRS relative to healthy volunteers. Moreover,
changes in ACC-Glx concentrations were associated with
changes in ACC-frontal connectivity in TRS. At baseline,
greater ACC-Glx concentrations were associated with more
severe negative symptoms and poorer cognitive performance,
Effect of riluzole: ACC-Glx
Group x time interaction
f = 4.46; p = 0.04a c
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Fig. 2 Effect of riluzole on voxel glutamate metabolite levels and anterior
cingulate cortex (ACC) connectivity in patients with treatment-resistant
schizophrenia (TRS) compared with healthy volunteers (HV). a There
was a significant group by time interaction for Glx (glutamate and gluta-
mine) levels in the ACC with administration of riluzole (p = 0.04). b
There was a significant group × time interaction for connectivity between
the ACC seed and a cluster within the anterior prefrontal cortex (aPFC,
p < 0.05, cluster corrected). c Change in ACC-functional connectivity z
scores in TRS compared with HV pre- and post-riluzole for the aPFC
cluster represented in b (p < 0.05, cluster corrected)
Table 2 Cerebrospinal fluid (CSF) corrected glutamate + glutamine
(Glx) values in the anterior cingulate cortex (ACC), and cerebral blood
flow in the anterior cingulate cortex and whole brain pre- and post-
riluzole. Data are presented as mean (standard deviation) and the statisti-
cal analysis shows the results of the group by time interaction tested using
a repeated measures ANOVA
Patients Healthy volunteers
Pre Post Pre Post Group × time interaction
ACC Glx 22.69 (7.05) 19.52 (4.79) 20.37 (4.19) 21.57 (4.97) F = 4.46; df = 35; p = 0.04
ACC CBF 44.99 (7.51) 45.13 (7.34) 44.03 (6.36) 43.93 (5.02) F = 0.02; df = 35; p = 0.90
Whole brain CBF 40.17 (6.67) 40.85 (7.22) 39.48 (5.81) 39.52 (5.25) F = 0.15; df = 35; p = 0.70
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adding to prior evidence for magnitude of regional glutamate
alterations in schizophrenia correlating with severity of nega-
tive and cognitive symptoms (Merritt et al. 2013). We did not
observe any difference in rCBF in the ACC or whole brain of
patients or controls in response to riluzole, suggesting that
observed changes in Glx and functional connectivity are not
secondary to non-specific changes in cerebral blood flow.
Implications for understanding and treating
schizophrenia
A previous clinical study in patients with schizophrenia and
treatment-resistant symptoms showed that riluzole (at the
same daily dose used in the current study) added to risperi-
done resulted in a significant improvement in negative symp-
toms after 4 week-treatment relative to placebo (Farokhnia
et al. 2014). Our findings extend this study by showing for
the first time to our knowledge that riluzole has schizophrenia-
specific effects on glutamatergic signalling and brain connec-
tivity. Taken with our finding that negative and cognitive
symptoms were directly correlated with brain glutamate func-
tion, this indicates riluzole is acting to target dysfunctional
brain systems in schizophrenia linked to negative and cogni-
tive symptoms, supporting its further evaluation as an adjunc-
tive treatment for schizophrenia.
The reduction in Glx levels following riluzole in TRS rel-
ative to HV may suggest illness-related differences in gluta-
matergic signalling that become apparent when challenged
with riluzole. The molecular targets of riluzole may include
presynaptic calcium channels (Doble 1996) and/or excitatory
amino acid transporters (EAAT) (Frizzo et al. 2004), and in-
teraction at either or both of these sites could potentially im-
pact on the 1H-MRSGlx signal. A preclinical study using 13C-
MRS found that riluzole administration enhanced prefrontal
cortex glutamate metabolism, suggesting increased glutamate
release and cycling through the glutamate/GABA/glutamine
pathway (Chowdhury et al. 2008). This is counterintuitive
since riluzole reduces presynaptic release of glutamate
(Bellingham 2011; Doble 1996). However, since riluzole can
also increase glutamatergic clearance from the extra-synaptic
space (Frizzo et al. 2004), the net effect at the level of anMRS
voxel, and after 2 days of riluzole administration, may still be
an overall reduction in Glx. A limitation of our 1H-MRSmeth-
odology is that we are unable to measure glutamine and can-
not examine glutamate cycling, as would be possible with
13C-MRS. A recent 13C-MRS human study examining the
acute effects of ketamine found increased prefrontal glutamate
release (a ‘glutamate surge’), and loss of neurotransmission
fidelity (i.e. a mismatch between pre-synaptic glutamate re-
lease and post-synaptic activity) which was associated with
the induction of psychotomimetic experiences (Abdallah
et al. 2018). If riluzole does indeed ameliorate synaptic
NMDA receptor-mediated neurotransmission in disease states
characterised by hyperglutamatergia, then our observation of
normalisation of ACC-aPFC connectivity in TRS with
riluzole may reflect improvements in fidel i ty of
neurotransmission.
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Fig. 4 Pre-riluzole associations between anterior cingulate cortex (ACC)
glutamate and glutamine (Glx) levels/functional connectivity z scores
(between ACC and aPFC cluster identified in Fig. 2b) with Auditory
Verbal Learning Test (AVLT) scores and negative symptom severity. a
Higher levels of ACC Glx are associated with reduced AVLT scores in
TRS (r = − 0.63; p = 0.002). b In TRS, higher levels of ACC Glx are
associated with greater severity of negative symptoms (r = 0.49; p =
0.03). c Increased ACC-functional connectivity is associated with higher
AVLT scores in TRS (r = 0.49; p = 0.04). Lines represent best-fit regres-
sion and r values represent Spearman rank correlation coefficients
Fig. 3 Association between changes in anterior cingulate cortex (ACC)
glutamate and glutamine (Glx) levels and changes in ACC-functional
connectivity (with anterior prefrontal cortex (aPFC) cluster defined in
Fig. 2b) following riluzole. aBaseline ACC-Glx correlates inversely with
degree of functional connectivity between ACC and aPFC cluster in TRS
(r = − 0.46; p = 0.047) but not HV (r = 0.09; p = 0.74). b Following
riluzole challenge, no significant association is observed between ACC-
Glx and functional connectivity between ACC and aPFC cluster in TRS
(r = − 0.16; p = 0.52) or HV (r = 0.14; p = 0.61). c Change in ACC-Glx
levels correlated inversely with change in functional connectivity be-
tween the ACC and aPFC cluster in the TRS group (r = − 0.52; p =
0.02) but not HV group (r = 0.01; p = 0.98). Lines represent best fit re-
gression and r values represent Spearman rank correlation coefficients
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Previous drug studies targeting glutamatergic neurotrans-
mission in schizophrenia have been disappointing. Broadly,
two families of drugs have been examined: drugs that increase
NMDA receptor activity (such as glycine and bitopertin)
(Buchanan et al. 2007; Singer et al. 2015) and drugs that
inhibit glutamate release (mGluR2/3 agonists) (Li et al.
2015). Riluzole’s mechanism of action is distinct from those
previously trialled, and based on the neurochemical and
neurofunctional outcomes of the present study may represent
a viable novel therapeutic avenue, especially in treatment-
resistant schizophrenia.
The effect of riluzole on connectivity between the ACC
and frontal cortex was significant for one seed in the ACC.
This may reflect the recognised functional heterogeneity of
the ACC (Margulies et al. 2007). The ACC seed identified
in this study has previously been observed to show functional
connectivity with prefrontal regions associated with higher
order cognitive functions (e.g. working memory) (Margulies
et al. 2007), which complements our observation of a pre-
riluzole direct relationship between degree of ACC-aPFC con-
nectivity and magnitude of verbal learning scores in patients.
However, our study was not designed to test the specificity of
sub-regional effects, and further work mapping the functional
connectivity of the ACC in TRS is required to determine this.
Although baseline Glx levels were numerically higher in the
schizophrenia group than the healthy volunteers, consistent
with some prior evidence (Merritt et al. 2016), this was not
statistically significant (p = 0.24), which could be due to a lack
of power. Indeed, the effect size for baseline ACC-Glx differ-
ence between patients and healthy volunteers was 0.40. For
two independent samples, an effect size of 0.40 requires a total
sample size of 200 to provide 80% power to detect a signifi-
cant difference between groups (α = 0.05, two tailed).
Strengths and limitations
The strength of this study is that we assured treatment adher-
ence (eTable 1) and excluded psychoactive substance use dur-
ing the study, which reduces the heterogeneity of the sampled
patient population (Howes and Kapur 2014). Furthermore, the
use of multimodal imaging techniques provides comprehen-
sive insight into neurochemical and neurofunctional alter-
ations associated with riluzole administration.
The absence of a placebo conditionmeans results cannot be
attributed to riluzole specifically. However, the inclusion of a
healthy control group controls for non-specific effects on im-
aging outcomes, and the fact that subjects were blind to the
hypotheses and the study used imaging outcomes makes it
unlikely that outcomes were confounded by placebo effects.
Nevertheless, it would be useful to test this further with the
inclusion of a placebo group. Although psychopathology
scores were assessed pre-riluzole, repeat measures were not
recorded post-riluzole. This was based on evidence from the
only previous study to examine the clinical efficacy of riluzole
in schizophrenia which did not observe significant improve-
ments in psychopathology until 4 weeks of treatment
(Farokhnia et al. 2014). Future longitudinal studies should
therefore include re-assessments of psychopathology, along-
side neuroimaging.
Although participants were excluded if receiving medica-
tion with recognised glutamatergic activity, there is evidence
that non-clozapine antipsychotic administration can reduce
ACC-glutamate metabolite levels (Egerton et al. 2017;
Egerton et al. 2018). While it is not generally feasible to re-
cruit a cohort of individuals with TRS who are medication
free, the fact that this is a repeated measures study and there
were no changes in antipsychotic treatment during the study
suggests the changes in Glx observed with riluzole are unlike-
ly to be related to medication effects. As we did not include a
treatment-responsive patient group for comparison, we cannot
specifically attribute our findings to treatment-resistant
schizophrenia. Further work is required to determine whether
the effects of riluzole on Glx and ACC-frontal connectivity
may differ in patients who respond well to antipsychotic med-
ication compared to those with treatment-resistant illness.
Although the observed group × time interaction for ACC-
Glx was significant, the effect of riluzole in decreasing ACC-
Glx in TRS in absolute terms was at a trend significance level
(t = 2.08; p = 0.05). This may reflect insufficient power in the
current study. Moreover, results of correlation analyses with
relatively small sample sizes should be interpreted with cau-
tion, and replication of our findings in larger cohorts is
required.
A limitation of 1H-MRS at 3-T field strength is the inability
to reliably quantify glutamine concentrations, owing to over-
lapping resonances between glutamate and glutamine. Thus, it
was not possible to examine the relative changes in glutamine
and glutamate concentrations in response to riluzole as has
previously been performed (Brennan et al. 2010).
Furthermore, we are unable to comment on the relative con-
tribution of glutamate or glutamine to the ACC changes ob-
served. Finally, as a methodology, 1H-MRS is limited by an
inability to precisely identify the location of glutamatergic
metabolites within a region of interest (i.e. intracellular versus
extracellular, presynaptic versus postsynaptic, and neuron ver-
sus astrocyte/glia).
Conclusion
Our findings add to evidence that glutamatergic dysfunction
contributes to the pathophysiology of schizophrenia by show-
ing that negative and cognitive symptoms are directly associ-
ated with levels of Glx, and that a glutamatergic modulator,
riluzole, modulates Glx and frontal cortical connectivity in
patients relative to controls. Future studies incorporating
Psychopharmacology
neuroimaging are required to investigate if riluzole-associated
alterations in frontal glutamatergic metabolites and associated
functional connectivity persist over longer treatment periods
and are associated with clinical efficacy to help inform the
potential of riluzole as an adjunctive treatment for
schizophrenia.
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